Takeda (OTCPK:TKPYY)
(4502.T) is no longer the sleeper pick it once was, as the local shares
of Japan's largest drug company have risen more than 25% year to date
and close to 35% over the past year (the ADRs have done well too, just
not as well as the local shares). Even so, patient investors should be
looking at the potential of high single-digit appreciation from here as
the company continues to realize the benefits of its restructuring
initiatives and reports on key clinical studies
Read more here:
Takeda Offers Restructuring And Portfolio Upside
No comments:
Post a Comment